Kaisa Huhtinen, Uniogen´s Oncology Clinical Manager, has a deep understanding of ovarian cancer diagnostics as a PhD and an Associate Professor. Kaisa is participating in the European Society of Medical Oncology (ESMO)– congress held in Barcelona the 13th – 17th of September in 2024 where the latest findings of cancer diagnostics are presented. 

How did you end up being an expert in ovarian cancer diagnostics? 

“I did my PhD studies in endometriosis disease and one of the key questions was to improve endometriosis diagnostics and especially differential diagnostics from ovarian cancer.  It got me interested in ovarian cancer and its diagnostics. Before I joined Uniogen, I focused many years on ovarian cancer research.” 

What is the driving force in your current job? 

“There is still much to improve cancer diagnostics, and I really want to see new technologies, like our ovarian cancer glycovariant immunoassay, benefit the patients. Right now, I am interested in developing research findings to a product to be accepted for clinical use.” 

What are your expectations from the upcoming congress? 

“I am very excited to participate ESMO and see the latest results presented there. I look forward updating my knowledge with the most recent research results and hope to meet key opinion leaders and potential partners as well.” 

What new clinical information Uniogen´s ovarian cancer test brings to the field? 

“Our results show that the CA125 glycovariant immunoassays developed at Uniogen improve ovarian cancer diagnostics especially in the most difficult subgroups such as patients with moderately increased CA125 or early-stage disease. In my opinion the assays have lots of potential.” 

How do you relax and clear your mind? 

“My most precious way to relax is gardening but also sports, nature and reading are important to me.”